Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | NEJM
Original Article from The New England Journal of Medicine — Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Related Articles
BPDCN: state of the art
Abstract. The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop
Article of the Week, Suggested by the BPDCN International Registry – OncoDaily
Article of the Week, Suggested by the BPDCN International Registry / Astghik Voskanyan, Blastic Plasmacytoid Dendritic Cell Neoplasm, BPDCN, BPDCN
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop
Homes for Healers
Meet Houston’s premier real estate agent for medical professionals. Whether you are moving within the city or relocating for the Texas Medical Center, I offer…
Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review
The diagnosis of myeloid neoplasms with plasmacytoid dendritic cell (pDC) differentiation can be challenging due to immunophenotypic overlap requiring detailed characterization by flow cytometry an…
Welcome! You are invited to join a webinar: IACH Webinar- Post #ASH24: the Most Important MPN Studies. After registering, you will receive a confirmation email about joining the webinar.
Speaker: Naveen Pemmaraju Prof. Naveen Pemmaraju completed his Internal Medicine training at Johns Hopkins, in the Osler Medical Program, he subsequently completed both hematology and…
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…